Vitamin B12 may hold the key to easing acute pancreatitis, not by lowering inflammation, but by enhancing energy production in pancreatic cells.
Scientists have uncovered a surprising ally in the fight against acute
pancreatitis: vitamin B12.
Through genetic analysis and mouse model experiments, researchers
showed that higher vitamin B12 levels can significantly reduce the severity of
this often-deadly condition.
Acute
Pancreatitis: A Deadly Digestive Threat
Acute pancreatitis (AP) is a serious gastrointestinal
condition that affects people of all ages and is a leading cause of hospital
admissions worldwide. Around 1 in 5 patients develop moderate to severe forms
of the disease, which are linked to high rates of death and long-term
disability. Even those who survive often face lasting complications that
significantly reduce their quality of life. Despite its impact, there is still
no clear consensus on the best way to treat acute pancreatitis. In particular,
there is an urgent need for medications that can prevent early damage to the
pancreas.
To address this, a research team led by Dr. Chuanwen
Fan, from West China Fourth Hospital at Sichuan University and Linköping
University in Sweden, conducted a study under the supervision of Prof. Dr.
Xianming Mo at Sichuan University’s West China Hospital. Their goal was to
explore whether vitamin B12 could help prevent or reduce the severity of acute
pancreatitis by using both human genetic data and animal models.
The researchers began by analyzing large-scale
genome-wide association studies (GWAS) to identify genetic links to
pancreatitis. They then used Mendelian randomization, a method that leverages
genetic variation to study the effects of specific nutrients, to examine
whether one-carbon metabolism nutrients were connected to pancreatitis risk.
Their results showed a strong association between higher blood levels of
vitamin B12 and a lower risk of developing several forms of pancreatitis.
Vitamin B12’s
Protective Power Revealed
Next, the team determined whether vitamin B12
displayed protective and potential therapeutic effects using experimental
models of pancreatitis in CD320 knockout mice, which lack a key gene
responsible for vitamin B12 absorption. Two distinct models of pancreatitis
were used in the study: one to observe early pancreatic injury responses, and
the other to track the pathological progression of acute pancreatitis.
The results
revealed that VB12 directly protects acinar cells from necrosis during the
early stages of acute pancreatitis and subsequently reduces T lymphocyte
infiltration. Notably, artificially increasing serum B12 levels before and
after the induction of pancreatitis not only reduced the severity of the
condition but also promoted tissue repair after pancreatic injury.
Interestingly, despite vitamin B12’s known role in the
one-carbon metabolism pathway, its protective effects in pancreatitis were not
mediated through the reduction of homocysteine or the glutathione (GSH)
pathways, as was previously hypothesized. Instead, vitamin B12 was found to
enhance ATP production in pancreatic tissue, thereby reducing acinar cell
necrosis and preventing disease progression. ATP supplementation in
CD320-deficient mice also alleviated pancreatic damage, further supporting the
hypothesis that vitamin B12’s protective effects result from improved cellular
energy supply rather than oxidative stress regulation.
A Path Toward
Future Therapies
“These exciting new findings add to the growing
evidence that vitamin B12 can reduce the severity of acute pancreatitis by
increasing ATP levels in pancreatic tissue, offering novel insights into
potential therapeutic strategies for this disease. This study lays a robust
foundation for future clinical applications of vitamin B12 in managing acute
pancreatitis,” Prof. Mo concludes.
Reference: “Vitamin B12 protects necrosis of acinar cells in pancreatic tissues with acute pancreatitis” by Yulin Chen, Xue Li, Ran Lu, Yinchun Lv, Yongzi Wu, Junman Ye, Jin Zhao, Li Li, Qiaorong Huang, Wentong Meng, Feiwu Long, Wei Huang, Qing Xia, Jianbo Yu, Chuanwen Fan and Xianming Mo, 15 October 2024, MedComm.
No comments:
Post a Comment